HUP9802424A2 - Farnezil-transzferáz inhibitor hatású 2-kinolon-származékok, e vegyületeket tartalmazó gyógyászati készítmények, eljárás előállításukra és alkalmazásuk - Google Patents

Farnezil-transzferáz inhibitor hatású 2-kinolon-származékok, e vegyületeket tartalmazó gyógyászati készítmények, eljárás előállításukra és alkalmazásuk

Info

Publication number
HUP9802424A2
HUP9802424A2 HU9802424A HUP9802424A HUP9802424A2 HU P9802424 A2 HUP9802424 A2 HU P9802424A2 HU 9802424 A HU9802424 A HU 9802424A HU P9802424 A HUP9802424 A HU P9802424A HU P9802424 A2 HUP9802424 A2 HU P9802424A2
Authority
HU
Hungary
Prior art keywords
alkyl
carbonyl
alkoxy
amino
hydroxy
Prior art date
Application number
HU9802424A
Other languages
English (en)
Inventor
Patrick René Angibaud
David William End
Gérard Charles Sanz
Marc Gaston Venet
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of HUP9802424A2 publication Critical patent/HUP9802424A2/hu
Publication of HUP9802424A3 publication Critical patent/HUP9802424A3/hu
Publication of HU224032B1 publication Critical patent/HU224032B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Az (I) általánős képletű vegyületek - a képletben X jelentése őxigén-vagy kénatőm. R1 jelentése hidrőgénatőm, alkil-, Ar1-, Ar2-alkil-,kinőlinil-alkil-, piridil-alkil-, hidrőxi-alkil-, alkőxi-alkil-, mőnő-vagy dialkil-aminő-alkil-, aminő-alkil-csőpőrt, vagy Alk1-C(=O)-R9,Alk1-S(=O)-R9, Alk1-S(=O)2-R9 általánős képletű csőpőrt, R2 és R3jelentése egymástól függetlenül hidrőgén- vagy halőgénatőm, hirőxil-,cianő-, alkil-, alkőxi-, hidrőxi-alkőxi-, alkőxi-alkőxi-, aminő-alkőxi-, mőnő- vagy dialkil-aminő-alkőxi-, Ar1-, Ar2-alkil-, Ar2-őxi-,Ar2-alkőxi-, hidrőxi-karbőnil-, alkőxi-karbőnil-, trihalőgén-metil-,trihalőgén-metőxi-, alkenilcsőpőrt, vagy R2 és R3 egymással szőmszédőshelyzetben együtt -O-CH2-O-, -O-CH2-CH2-O-, -O-CH=CH-, -O-CH2-CH2-, -O-CH2-CH2-CH2-, -CH=CH-CH=CH- képletű csőpőrtőt is alkőthatnak, R4 ésR5 jelentése egymástól függetlenül hidrőgén- vagy halőgénatőm, Ar1-,alkil-, alkőxi-alkil-, alkőxi-, alkil-tiő-, aminő-, hidrőxi-karbőnil-,alkőxi-karbőnil-, alkil-S(O)-alkil- vagy alkil-S(O)2-alkil-csőpőrt, R6 és R7 jelentése egymástól függetlenül hidrőgén- vagyhalőgénatőm, cianő-, alkil-, alkőxi-, Ar2-őxi-csőpőrt R8 jelentésehidrőgénatőm, alkil-, cianő-, hidrőxi-karbőnil-, alkőxi-karbőnil-,alkil-karbőnil-alkil-, cianő-alkil-, alkőxi-karbőnil-alkil-, hidrőxi-karbőnil-alkil-, aminő-alkil-, mőnő- vagy dialkil-aminő-alkil-,halőgén-alkil-, alkőxi-alkil-, aminő-karbőnil-alkil-, Ar1-, Ar2-alkőxi-alkil-, alkil-tiő-alkil-csőpőrt, R10 jelentése hidrőgénatőm,alkil-, alkőxicsőpőrt vagy halőgénatőm, R11 jelentése hidrőgénatőmvagy alkilcsőpőrt - farnezil-transzferáz gátló aktivitásűkkövetkeztében gyógyszerkészítmények hatóanyagaként használhatók. (I) ŕ
HU9802424A 1995-10-31 1996-10-25 Farnezil-transzferáz inhibitor hatású 2-kinolon-származékok HU224032B1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95202945 1995-10-31
PCT/EP1996/004661 WO1997016443A1 (en) 1995-10-31 1996-10-25 Farnesyl transferase inhibiting 2-quinolone derivatives

Publications (3)

Publication Number Publication Date
HUP9802424A2 true HUP9802424A2 (hu) 1999-10-28
HUP9802424A3 HUP9802424A3 (en) 2003-02-28
HU224032B1 HU224032B1 (hu) 2005-05-30

Family

ID=8220785

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9802424A HU224032B1 (hu) 1995-10-31 1996-10-25 Farnezil-transzferáz inhibitor hatású 2-kinolon-származékok

Country Status (29)

Country Link
US (1) US5968952A (hu)
EP (2) EP1019395B1 (hu)
JP (1) JP4257869B2 (hu)
KR (1) KR100417620B1 (hu)
CN (1) CN1101391C (hu)
AR (1) AR004699A1 (hu)
AT (2) ATE212627T1 (hu)
AU (1) AU712435B2 (hu)
CA (1) CA2231143C (hu)
CY (1) CY2287B1 (hu)
CZ (1) CZ290954B6 (hu)
DE (2) DE69632751T2 (hu)
DK (1) DK1019395T3 (hu)
EA (1) EA000719B1 (hu)
ES (2) ES2171736T3 (hu)
HK (2) HK1027576A1 (hu)
HU (1) HU224032B1 (hu)
IL (1) IL123567A (hu)
MY (1) MY116577A (hu)
NO (1) NO314037B1 (hu)
NZ (1) NZ321576A (hu)
PL (1) PL184168B1 (hu)
PT (1) PT1019395E (hu)
SI (1) SI1019395T1 (hu)
SK (1) SK282642B6 (hu)
TR (1) TR199800720T2 (hu)
TW (1) TW349948B (hu)
WO (1) WO1997016443A1 (hu)
ZA (1) ZA969087B (hu)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69807222T2 (de) 1997-06-02 2003-04-17 Janssen Pharmaceutica Nv (imidazol-5-yl)methyl-2-quinolinone derivativen als inhibitoren von proliferation der glatten muskelzellen
US6565831B1 (en) 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6319939B1 (en) 1997-12-11 2001-11-20 Janssen Pharmaceutica N.V. Retinoic acid mimetic anlides
DK1097150T3 (da) * 1998-06-16 2004-07-26 Sod Conseils Rech Applic Imidazolylderivater
US6420555B1 (en) 1998-06-16 2002-07-16 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Imidazolyl derivatives
DE69912790T2 (de) 1998-07-06 2004-09-23 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitoren zur behandlung von arthropathien
CN1152716C (zh) 1998-07-06 2004-06-09 詹森药业有限公司 具体***线感受性的法呢基蛋白质转移酶抑制剂
FR2780892B1 (fr) * 1998-07-08 2001-08-17 Sod Conseils Rech Applic Utilisation d'inhibiteurs de prenyltransferases pour preparer un medicament destine a traiter les pathologies qui resultent de la fixation membranaire de la proteine g heterotrimerique
ES2237125T3 (es) * 1998-08-27 2005-07-16 Pfizer Products Inc. Derivados de quinolin-2-ona utiles como agentes anticancerigenos.
OA11645A (en) 1998-08-27 2004-11-16 Pfizer Prod Inc Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents.
US6284755B1 (en) 1998-12-08 2001-09-04 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6316436B1 (en) 1998-12-08 2001-11-13 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
DK1140935T3 (da) 1998-12-23 2003-09-01 Janssen Pharmaceutica Nv 1,2-anellerede quinolinderivater
WO2000047574A1 (en) * 1999-02-11 2000-08-17 Pfizer Products Inc. Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents
US6143766A (en) * 1999-04-16 2000-11-07 Warner-Lambert Company Benzopyranone and quinolone inhibitors of ras farnesyl transferase
EP1420015A1 (en) * 1999-06-11 2004-05-19 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Imidazolyl derivatives
EP1106612B1 (en) 1999-11-30 2004-02-11 Pfizer Products Inc. Quinoline derivatives useful for inhibiting farnesyl protein transferase
HN2000000266A (es) * 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
EP1267848B1 (en) 2000-02-24 2007-10-17 Janssen Pharmaceutica N.V. Dosing regimen comprising a farnesyl protein transferase inhibitor for the treatment of cancer
US20030186925A1 (en) * 2000-02-29 2003-10-02 Palmer Peter Albert Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
US20030027808A1 (en) * 2000-02-29 2003-02-06 Palmer Peter Albert Farnesyl protein transferase inhibitor combinations with platinum compounds
AU2001244167A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
CA2397256A1 (en) * 2000-02-29 2001-09-07 Mary Ellen Margaret Rybak Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
AU2001254672A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with an her2 antibody
US20030212008A1 (en) * 2000-02-29 2003-11-13 Palmer Peter Albert Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
WO2001064194A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with camptothecin compounds
EP1263437A2 (en) * 2000-02-29 2002-12-11 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with vinca alkaloids
JP2003525239A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ タキサン化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
WO2001064217A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
AU2001252147A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations
US6844357B2 (en) * 2000-05-01 2005-01-18 Pfizer Inc. Substituted quinolin-2-one derivatives useful as antiproliferative agents
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
EP1322636A1 (en) * 2000-09-25 2003-07-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6- (substituted phenyl)methyl]-quinoline and quinazoline derivatives
EP1322644A1 (en) * 2000-09-25 2003-07-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
DE60118225T2 (de) * 2000-09-25 2007-05-03 Janssen Pharmaceutica N.V. Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren
ATE434615T1 (de) 2000-11-21 2009-07-15 Janssen Pharmaceutica Nv Farnesyltransferase hemmende benzoheterocyclische derivate
DE60118953T2 (de) * 2000-11-28 2007-01-11 Janssen Pharmaceutica N.V. Farnesyl-protein-transferasehemmer zur behandlung der entzündlichen darmerkrankung
CA2432137C (en) 2000-12-19 2010-12-21 Pfizer Products Inc. Crystal forms of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1h-quinolin-2-one, 2,3-dihydroxybutanedioate salts and method of production
ES2260316T3 (es) * 2000-12-27 2006-11-01 Janssen Pharmaceutica N.V. Derivados de quinazolina y quinolina 4-sustituidos que inhiben la farnesil transferasa.
ES2263684T3 (es) * 2000-12-27 2006-12-16 Janssen Pharmaceutica N.V. Derivados de 4-heterociclil-quinolina y -quinazolina que inhiben la farnesil transferasa.
ES2318000T3 (es) * 2001-02-15 2009-05-01 Janssen Pharmaceutica Nv Combinaciones de inhibidores de la farnesil-protein-transferasa con agentes antiestrogenos.
PT1373255E (pt) 2001-03-12 2005-05-31 Janssen Pharmaceutica Nv Processo para a preparacao de compostos de imidazole
US6740757B2 (en) 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
US7408063B2 (en) 2001-12-19 2008-08-05 Janssen Pharmaceutica, N.V. 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
ATE364384T1 (de) 2002-03-22 2007-07-15 Janssen Pharmaceutica Nv Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren
ATE336496T1 (de) 2002-04-15 2006-09-15 Janssen Pharmaceutica Nv Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
FR2841243B1 (fr) * 2002-06-19 2004-08-20 Servier Lab Nouveaux derives de 3-(4-oxo-4h-chromen-2yl)-(1h)-quinolein- 4-ones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20030125268A1 (en) * 2002-08-28 2003-07-03 Rybak Mary Ellen Margaret Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
FR2860235A1 (fr) * 2003-09-29 2005-04-01 Yang Ji Chemical Company Ltd Utilisation d'un compose de formule (i) inhibiteur de l'aromatase a des fins therapeutiques et composes de formule (i) en tant que tels
US20050272068A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. UCH-L1 expression and cancer therapy
EP2433634A3 (en) * 2004-09-17 2012-07-18 The Whitehead Institute for Biomedical Research Compounds, compositions and methods of inhibiting a-synuclein toxicity
RS52741B (en) 2004-11-05 2013-08-30 Janssen Pharmaceutica N.V. THERAPEUTIC USE OF FARNEZILTRANSPHERASE INHIBITORS AND PROCEDURES FOR MONITORING THEIR EFFICIENCY
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
US20070004660A1 (en) * 2005-06-10 2007-01-04 Baumann Christian A Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines
US20060281755A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US20060281769A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US7833339B2 (en) 2006-04-18 2010-11-16 Franklin Industrial Minerals Mineral filler composition
EP2545919A1 (en) 2005-12-23 2013-01-16 Link Medicine Corporation Treatment of synucleinopathies
WO2007124322A1 (en) * 2006-04-20 2007-11-01 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
DK2021335T3 (da) 2006-04-20 2011-09-05 Janssen Pharmaceutica Nv Heterocykliske forbindelser som C-FMS-kinasehæmmere
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
DE102007015709B4 (de) 2007-01-25 2009-09-03 Webasto Ag Fahrzeugdach
JP2010529122A (ja) 2007-06-05 2010-08-26 シェーリング コーポレイション 多環式インダゾール誘導体および癌の治療のためのｅｒｋ阻害剤としてのそれらの使用
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
US7932036B1 (en) 2008-03-12 2011-04-26 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
US8232402B2 (en) 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
WO2009117484A2 (en) 2008-03-18 2009-09-24 University Of South Florida Small molecule e2f inhibitor
BRPI0920927A2 (pt) 2008-11-13 2019-09-24 Link Medicine Corp derivados de azaquinolinona e usos dos mesmos
EP2483263B1 (en) 2009-09-30 2018-07-18 Merck Sharp & Dohme Corp. Heterocyclic compounds that are erk inhibitors
WO2011127192A2 (en) 2010-04-06 2011-10-13 Brigham Young University Antimetastatic compounds
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
JP6034784B2 (ja) 2010-07-28 2016-11-30 ジャンセン ダイアグノスティックス，エルエルシー ファルネシルトランスフェラーゼ阻害剤による治療に対する急性白血病応答を判定するための方法
EP2616453A4 (en) * 2010-08-24 2014-07-02 Univ Brigham Young ANTIMETASTATIC COMPOUNDS
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
WO2013052465A1 (en) * 2011-10-02 2013-04-11 Trustees Of Boston University [1,3]dioxolo[4,5-g]quinoline-6(5h)thione and [1,3]dioxolo[4,5-g][1,2,4]triazolo[1,5-a]quinoline derivatives as inhibitors of the late sv40 factor (lsf) for use in treating cancer
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
CN104870454B (zh) 2012-08-07 2020-03-03 詹森药业有限公司 用于制备杂环酯衍生物的方法
WO2015119249A1 (ja) 2014-02-07 2015-08-13 国立大学法人東京医科歯科大学 筋形成促進剤、筋萎縮抑制剤、医薬組成物及びｔａｚ活性化剤
PT3277842T (pt) 2015-08-17 2019-09-05 Kura Oncology Inc Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase
EP3133066A1 (en) * 2015-08-21 2017-02-22 Merck Patent GmbH Hydrophilic compounds for optically active devices
EP3133065A1 (en) 2015-08-21 2017-02-22 Merck Patent GmbH Compounds for optically active devices
US9815790B2 (en) 2015-08-27 2017-11-14 Janssen Pharmaceutica Nv Chemically modified quinoline and quinolone derivatives useful as CB-1 inverse agonists
LT3534885T (lt) 2016-11-03 2021-07-12 Kura Oncology, Inc. Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui
EP3363793A1 (en) 2017-02-15 2018-08-22 Merck Patent GmbH Hydrophobic compounds for optically active devices
EP3363786A1 (en) 2017-02-15 2018-08-22 Merck Patent GmbH Compounds for optically active devices
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
TW202108170A (zh) 2019-03-15 2021-03-01 美商庫拉腫瘤技術股份有限公司 以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3900501A (en) * 1970-12-23 1975-08-19 Hoffmann La Roche Benzophenone intermediates for 7-lower alkanoyl benzodiazepines
IL65709A (en) * 1981-05-18 1986-01-31 Chevron Res Electroactive polymers
JPS63275548A (ja) * 1987-05-02 1988-11-14 Res Inst For Prod Dev ｏ−アミノベンゾイル化合物の製造方法
CA2002859C (en) * 1988-11-29 1998-12-29 Jean P. F. Van Wauwe Method of treating epithelial disorders
CA2002864C (en) * 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
EP0574992A1 (en) * 1992-06-17 1993-12-22 Glaxo Group Limited 5-(1,2,4-Triazol-1-ylmethyl)-3H-isobenzofuran-1-one derivatives, their preparation and use as aromatase inhibitors
ES2134971T3 (es) * 1994-04-15 1999-10-16 Takeda Chemical Industries Ltd Derivado de acido octahidro-2-naftaleno-carboxilico, su produccion y uso.

Also Published As

Publication number Publication date
JPH11514635A (ja) 1999-12-14
EA199800395A1 (ru) 1998-10-29
CY2287B1 (en) 2003-07-04
DE69618999D1 (de) 2002-03-14
DE69632751D1 (de) 2004-07-22
SI1019395T1 (en) 2002-06-30
NO314037B1 (no) 2003-01-20
EP1019395A1 (en) 2000-07-19
CN1101391C (zh) 2003-02-12
PL328230A1 (en) 1999-01-18
TW349948B (en) 1999-01-11
MY116577A (en) 2004-02-28
IL123567A (en) 2002-11-10
HU224032B1 (hu) 2005-05-30
CZ127298A3 (cs) 1998-12-16
ZA969087B (en) 1998-04-29
ATE269322T1 (de) 2004-07-15
AU7493396A (en) 1997-05-22
EP1106610B1 (en) 2004-06-16
ES2171736T3 (es) 2002-09-16
PL184168B1 (pl) 2002-09-30
TR199800720T2 (xx) 1998-09-21
EP1106610A1 (en) 2001-06-13
MX9802067A (es) 1998-08-30
CN1200732A (zh) 1998-12-02
WO1997016443A1 (en) 1997-05-09
CA2231143A1 (en) 1997-05-09
JP4257869B2 (ja) 2009-04-22
US5968952A (en) 1999-10-19
AU712435B2 (en) 1999-11-04
DK1019395T3 (da) 2002-05-06
EA000719B1 (ru) 2000-02-28
EP1019395B1 (en) 2002-01-30
SK282642B6 (sk) 2002-10-08
IL123567A0 (en) 1998-10-30
CZ290954B6 (cs) 2002-11-13
PT1019395E (pt) 2002-07-31
HK1036064A1 (en) 2001-12-21
ATE212627T1 (de) 2002-02-15
KR19990063639A (ko) 1999-07-26
NO980928D0 (no) 1998-03-04
AR004699A1 (es) 1999-03-10
KR100417620B1 (ko) 2004-05-27
HUP9802424A3 (en) 2003-02-28
CA2231143C (en) 2005-06-21
ES2233557T3 (es) 2005-06-16
NO980928L (no) 1998-04-29
SK55698A3 (en) 1999-02-11
DE69618999T2 (de) 2002-09-26
HK1027576A1 (en) 2001-01-19
DE69632751T2 (de) 2005-08-04
NZ321576A (en) 1999-05-28

Similar Documents

Publication Publication Date Title
HUP9802424A2 (hu) Farnezil-transzferáz inhibitor hatású 2-kinolon-származékok, e vegyületeket tartalmazó gyógyászati készítmények, eljárás előállításukra és alkalmazásuk
HUP9900185A2 (hu) Farnezil protein-transzferáz inhibitor hatású (imidazol-5-il)-metil-2-kinolinon-származékok, előállításuk, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
TW325458B (en) Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer
TNSN04208A1 (fr) Derives de n-[phenyl(piperidin-2-yl)methyl] benzamide, leur preparation et leur application en therapeutique
HUP0000613A2 (hu) Fájdalomcsillapító hatású piperidinszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
HUP0001285A2 (hu) Proteáz inhibitor hatású pirrolidinszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
HUP9802937A2 (hu) Benzo[g]kinolin-származékok, e vegyületeket tartalmazó gyógyászati készítmények, eljárás előállításukra és alkalmazásuk
HUP0105414A2 (hu) Pirrolo-izokinolin-, azepino- és diazepino-indol-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
NO307053B1 (no) 0-alkylerte rapamycinderivater samt farmasøytiske preparater inneholdende derivatene
DE69930926D1 (de) Benzolsulfonamid-derivate und ihre anwendung als arzneimittel
HUP0303043A2 (hu) Orrgyógyászatilag aktív vegyületek
HUP0203841A2 (en) 5-membered heteroaromatic compounds and use thereof for preparation of pharmaceutical compositions, and pharmaceutical compositions containing them
NO304379B1 (no) 11,21-bisfenyl-19-norpregnan-derivater, anvendelse derav og farmas°ytiske preparater inneholdende slike derivater
HUP0100558A2 (hu) S-Oxid- és S,S-dioxid-tetrahidrotiopirán-fenil-oxazolidinon-származékok, e vegyületek alkalmazása gyógyászati készítmények előállítására, valamint eljárás e vegyületek gátló hatásának meghatározására humán-monoamin-oxidázzal szemben
HUP9700005A2 (hu) 2-Ureido-benzamid-származékok és ilyeneket hatóanyagként tartalmazó gyógyszerkészítmények
KR950703554A (ko) 피페라진 유도체 및 그의 염(piperazine derivatives and salts thereof)
KR890003691A (ko) 피페리딘 유도체 및 그를 함유하는 부정맥을 위한 치료예방제
MA23639A1 (fr) Derives pyrrocarbazole, leur preparation, les compositions pharmaceutiques les contenant, leur utilisation dans le traitement des tumeurs malignes.
DE3677471D1 (de) Pyrrolidinylamidesterderivate mit antiprolylendopeptidaseaktivitaet, ihre herstellung, ihre verwendung und sie enthaltende pharmazeutische zubereitungen.
NO921382L (no) Amidinofenylalaninderivater, samt fremstilling, anvendelse og preparater inneholdende forbindelsene
KR900004714A (ko) 신규의 3,4-디아미노 퀴놀린 및 피리딘계 화합물
IL110831A0 (en) Quinazolinone-containing pharmaceutical compositions and methods for the use thereof
BR9913183A (pt) Composto, uso do mesmo, processo para prepará-lo, processo para tratar um indivìduo humano ou animal, e, composição farmacêutica
HUP0102025A2 (hu) Diaril-1,3,4-oxadiazolon-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0101098A1 (hu) Szteptograminszármazékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
HFG4 Patent granted, date of granting

Effective date: 20050322

MM4A Lapse of definitive patent protection due to non-payment of fees